Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

36.22
+0.35771.00%
Post-market: 36.16-0.0550-0.15%19:30 EDT
Volume:3K
Turnover:90.56K
Market Cap:88.01M
PE:- -
High:36.23
Open:36.18
Low:35.96
Close:35.86
52wk High:39.48
52wk Low:33.59
Shares:2.43M
Float Shares:2.43M
Volume Ratio:0.36
T/O Rate:0.10%
Dividend:0.33
Dividend Rate:0.91%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lonza Strengthens Board with Nomination of Biotech Veteran Pearl Huang

TIPRANKS
·
Sep 30

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS
·
Sep 30

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

Reuters
·
Sep 30

Actinogen Medical Adds Modest Number of New Shares to ASX Listing

TIPRANKS
·
Sep 30

Marvel Biosciences Raises $1.6 Million to Advance Lead Neurology Drug Into Phase 1 Trials

TIPRANKS
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 30

I'm in My 50s. My Mother Died from Alzheimer's. Do I Need Long-Term-Care Insurance?

Dow Jones
·
Sep 30

AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says

MT Newswires Live
·
Sep 29

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live
·
Sep 29

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Reuters
·
Sep 29

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29